Hemodialysis vascular access dysfunction from basic biology to clinical intervention.

Abstract

Hemodialysis vascular access dysfunction is a major cause of morbidity and hospitalization in the hemodialysis population at a cost of over 1 billion dollars per annum. Venous stenosis and thrombosis as a result of venous neointimal hyperplasia are the major causes of hemodialysis vascular access dysfunction. Despite the magnitude of the clinical problem, there are currently no effective therapies for this condition. We believe that this could be because of an inadequate understanding of the pathogenesis of this condition. At a histological level, venous neointimal hyperplasia (both in human specimens and in a pig model) is characterized by the presence of smooth muscle cells/myofibroblasts, microvessel formation (angiogenesis), and the accumulation of extracellular matrix components, all of which could be potential targets for therapeutic intervention. In particular, polytetrafluoroethylene dialysis access grafts could be the ideal clinical model for testing out novel local therapies to block neointimal hyperplasia. The current review describes the lesion of venous neointimal hyperplasia in human samples and in a pig model and suggests possible future directions for the development of effective local therapies for this condition.

• Authors: Prabir Roy-Chaudhury, Burnett S Kelly, Ashwath Narayana, Pankaj Desai, Murad Melhem, Rino Munda, Heather Duncan, Sue C Heffelfinger
• Journal: Advances in renal replacement therapy (Adv Ren Replace Ther) Vol. 9 Issue 2 Pg. 74-84 (Apr 2002) ISSN: 1073-4449 [Print] United States
• PMID: 12085383 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright 2002 by the National Kidney Foundation, Inc.

Topics

• Arteriovenous Shunt, Surgical
• Graft Occlusion, Vascular (physiopathology, therapy)
• Humans
• Kidney Failure, Chronic (therapy)
• Renal Dialysis